Literature DB >> 10430937

The role of MHC class II molecules in susceptibility to type I diabetes: identification of peptide epitopes and characterization of the T cell repertoire.

C C Chao1, H K Sytwu, E L Chen, J Toma, H O McDevitt.   

Abstract

Susceptibility to type I diabetes is linked to class II MHC alleles in both mouse and man. However, the molecular mechanisms by which MHC molecules mediate disease susceptibility are unknown. To analyze how I-A alleles predispose to, or prevent, the development of type I diabetes, we have chosen, as the first step, to investigate the immune response to an important islet cell protein in diabetes-susceptible and diabetes-resistant mice. MHC class II alleles conferring susceptibility and resistance to diabetes select completely different sets of immunogenic epitopes from the beta islet cell autoantigen glutamic acid decarboxylase 65. Peptide-binding studies, analysis of MHC restriction, and immunization with these peptide epitopes indicate that the two amino acid substitutions within the I-A(beta) chain that distinguish a diabetes-susceptibility from a diabetes-resistance allele are sufficient to alter peptide binding and MHC restriction and may also influence antigen presentation and the selection of the T cell repertoire. The data indicate that the molecular mechanisms for class II-mediated selection of immunodominant epitopes are complex and differ for each individual peptide epitope. Further study of the functional characteristics of the response to these epitopes should provide insight into mechanisms of MHC-mediated diabetes susceptibility.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10430937      PMCID: PMC17775          DOI: 10.1073/pnas.96.16.9299

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  28 in total

Review 1.  Type-I diabetes: a chronic autoimmune disease of human, mouse, and rat.

Authors:  L Castaño; G S Eisenbarth
Journal:  Annu Rev Immunol       Date:  1990       Impact factor: 28.527

2.  Direct evidence for the contribution of the unique I-ANOD to the development of insulitis in non-obese diabetic mice.

Authors:  T Miyazaki; M Uno; M Uehira; H Kikutani; T Kishimoto; M Kimoto; H Nishimoto; J Miyazaki; K Yamamura
Journal:  Nature       Date:  1990-06-21       Impact factor: 49.962

3.  The first external domain of the nonobese diabetic mouse class II I-A beta chain is unique.

Authors:  H Acha-Orbea; H O McDevitt
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

4.  Peptide motifs of HLA-DR4/DR53 (DRB1*0405/DRB4*0101) molecules.

Authors:  R Kinouchi; H Kobayasi; K Sato; S Kimura; M Katagiri
Journal:  Immunogenetics       Date:  1994       Impact factor: 2.846

Review 5.  MHC ligands and peptide motifs: first listing.

Authors:  H G Rammensee; T Friede; S Stevanoviíc
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

6.  Complexes generated by the binding of free peptides to class II MHC molecules are antigenically diverse compared with those generated by intracellular processing.

Authors:  N J Viner; C A Nelson; B Deck; E R Unanue
Journal:  J Immunol       Date:  1996-04-01       Impact factor: 5.422

7.  The NOD mouse: recessive diabetogenic gene in the major histocompatibility complex.

Authors:  M Hattori; J B Buse; R A Jackson; L Glimcher; M E Dorf; M Minami; S Makino; K Moriwaki; H Kuzuya; H Imura
Journal:  Science       Date:  1986-02-14       Impact factor: 47.728

8.  T helper cell subsets in insulin-dependent diabetes.

Authors:  J D Katz; C Benoist; D Mathis
Journal:  Science       Date:  1995-05-26       Impact factor: 47.728

9.  Prevention of diabetes in non-obese diabetic I-Ak transgenic mice.

Authors:  R M Slattery; L Kjer-Nielsen; J Allison; B Charlton; T E Mandel; J F Miller
Journal:  Nature       Date:  1990-06-21       Impact factor: 49.962

10.  Allele specificity of structural requirement for peptides bound to HLA-DRB1*0405 and -DRB1*0406 complexes: implication for the HLA-associated susceptibility to methimazole-induced insulin autoimmune syndrome.

Authors:  S Matsushita; K Takahashi; M Motoki; K Komoriya; S Ikagawa; Y Nishimura
Journal:  J Exp Med       Date:  1994-09-01       Impact factor: 14.307

View more
  19 in total

1.  Specificity of peptide selection by antigen-presenting cells homozygous or heterozygous for expression of class II MHC molecules: The lack of competition.

Authors:  Anish Suri; James J Walters; Osami Kanagawa; Michael L Gross; Emil R Unanue
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-07       Impact factor: 11.205

2.  Prophylactic and therapeutic suppression of experimental autoimmune encephalomyelitis by a novel bifunctional peptide inhibitor.

Authors:  Naoki Kobayashi; Paul Kiptoo; Hitomi Kobayashi; Rahmawati Ridwan; Stefan Brocke; Teruna J Siahaan
Journal:  Clin Immunol       Date:  2008-08-03       Impact factor: 3.969

3.  Long-term silencing of autoimmune diabetes and improved life expectancy by a soluble pHLA-DR4 chimera in a newly-humanized NOD/DR4/B7 mouse.

Authors:  Luis Pow Sang; Sai Majji; Sofia Casares; Teodor D Brumeanu
Journal:  Hum Vaccin Immunother       Date:  2013-12-11       Impact factor: 3.452

4.  Susceptible MHC alleles, not background genes, select an autoimmune T cell reactivity.

Authors:  Thomas Stratmann; Natalia Martin-Orozco; Valérie Mallet-Designe; Laurent Poirot; Dorian McGavern; Grigoriy Losyev; Cathleen M Dobbs; Michael B A Oldstone; Kenji Yoshida; Hitoshi Kikutani; Diane Mathis; Christophe Benoist; Kathryn Haskins; Luc Teyton
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

5.  Prevention of type I diabetes transfer by glutamic acid decarboxylase 65 peptide 206-220-specific T cells.

Authors:  Seon-Kyeong Kim; Kristin V Tarbell; Maija Sanna; Mary Vadeboncoeur; Tibor Warganich; Mark Lee; Mark Davis; Hugh O McDevitt
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-20       Impact factor: 11.205

6.  Double negative (CD3+ 4- 8-) TCR alphabeta splenic cells from young NOD mice provide long-lasting protection against type 1 diabetes.

Authors:  Beverly Duncan; Cristina Nazarov-Stoica; Jacqueline Surls; Margaret Kehl; Constantin Bona; Sofia Casares; Teodor-D Brumeanu
Journal:  PLoS One       Date:  2010-07-02       Impact factor: 3.240

7.  Genetic-induced variations in the GAD65 T-cell repertoire governs efficacy of anti-CD3/GAD65 combination therapy in new-onset type 1 diabetes.

Authors:  Damien Bresson; Matthew Fradkin; Yulia Manenkova; Diane Rottembourg; Matthias von Herrath
Journal:  Mol Ther       Date:  2009-08-18       Impact factor: 11.454

8.  Prevention of type 1 diabetes by gene therapy.

Authors:  Chaorui Tian; Jessamyn Bagley; Nathalie Cretin; Nilufer Seth; Kai W Wucherpfennig; John Iacomini
Journal:  J Clin Invest       Date:  2004-10       Impact factor: 14.808

9.  The role of HLA-DQ8 beta57 polymorphism in the anti-gluten T-cell response in coeliac disease.

Authors:  Zaruhi Hovhannisyan; Angela Weiss; Alexandra Martin; Martina Wiesner; Stig Tollefsen; Kenji Yoshida; Cezary Ciszewski; Shane A Curran; Joseph A Murray; Chella S David; Ludvig M Sollid; Frits Koning; Luc Teyton; Bana Jabri
Journal:  Nature       Date:  2008-11-27       Impact factor: 49.962

10.  Nature of T cell epitopes in lupus antigens and HLA-DR determines autoantibody initiation and diversification.

Authors:  Zhenhuan Zhao; Jiling Ren; Chao Dai; Carol C Kannapell; Hongyang Wang; Felicia Gaskin; Shu Man Fu
Journal:  Ann Rheum Dis       Date:  2018-09-25       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.